Eran Goren - DNA Biomed Director

DNA Stock  ILS 79.00  2.10  2.73%   

Director

Mr. Eran Goren serves as Independent Director at D.N.A Biomedical Solutions Ltd since February 26, 2014. He is a member of the Audit, Compensation and Financial Statements Auditing committees. His work experience includes the following roles Managing Partner at Fidlis Partners Ltd, Chairman at Trendline Information Communication Services Ltd and Investments Manager at Ellomay Capital Ltd . since 2014.
Age 59
Tenure 10 years
Phone972 3 970 5000
Webhttps://www.laser-detect.com

DNA Biomed Management Efficiency

The company has return on total asset (ROA) of (0.0375) % which means that it has lost $0.0375 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.2509) %, meaning that it generated substantial loss on money invested by shareholders. DNA Biomed's management efficiency ratios could be used to measure how well DNA Biomed manages its routine affairs as well as how well it operates its assets and liabilities.

Similar Executives

Showing other executives

DIRECTOR Age

Aharon AbramovichIsrael Discount Bank
65
Moshe AmitDelek Group
79
Joseph ShachakMizrahi Tefahot
72
Ilan BiranIsrael Discount Bank
69
HajYehia SamerBank Leumi Le Israel
48
Alejandro ElsztainDiscount Investment Corp
51
Yitzhak SharirBank Leumi Le Israel
66
Oran DrorAzrieli Group
45
Ron GazitMizrahi Tefahot
66
Nurit KrauszJerusalem
48
Ohad MaraniBank Leumi Le Israel
63
Hannah FeuerMizrahi Tefahot
62
Nurit SegalBank Leumi Le Israel
72
Niv AhituvAzrieli Group
74
Zipora SametBank Leumi Le Israel
71
Micha ChorinDiscount Investment Corp
45
Shmuel EshelJerusalem
62
Lior AmiJerusalem
49
Gideon SitermanMizrahi Tefahot
62
Moshe MatalonDiscount Investment Corp
63
Haim LevyBank Leumi Le Israel
77
D.N.A Biomedical Solutions Ltd. develops and commercializes laser spectrometry-based trace detection systems in Israel. D.N.A Biomedical Solutions Ltd. was founded in 2004 and is based in Ramat Gan, Israel. D N operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. DNA Biomed Solns (DNA) is traded on Tel Aviv Stock Exchange in Israel and employs 11 people.

Management Performance

DNA Biomed Solns Leadership Team

Elected by the shareholders, the DNA Biomed's board of directors comprises two types of representatives: DNA Biomed inside directors who are chosen from within the company, and outside directors, selected externally and held independent of DNA. The board's role is to monitor DNA Biomed's management team and ensure that shareholders' interests are well served. DNA Biomed's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, DNA Biomed's outside directors are responsible for providing unbiased perspectives on the board's policies.
Eran Goren, Director
Yacov Nimkovsky, External Director
Yeonatan Malca, CEO, Director
Rachel Shavit, External Director
Michael Gaft, Chief Scientist
Tony Klein, Vice President - Finance
Daniel Spira, Internal Auditor
Daniel Shapira, Internal Auditor
Zvika LTC, VP Programs
Zeev Bronfeld, Chairman of the Board and Director
Ronen Midbari, External Director

DNA Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is DNA Biomed a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards DNA Biomed in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, DNA Biomed's short interest history, or implied volatility extrapolated from DNA Biomed options trading.

Pair Trading with DNA Biomed

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if DNA Biomed position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in DNA Biomed will appreciate offsetting losses from the drop in the long position's value.

Moving together with DNA Stock

  0.71CLIS Clal Insurance EnterPairCorr

Moving against DNA Stock

  0.63BEZQ Bezeq Israeli TelecoPairCorr
The ability to find closely correlated positions to DNA Biomed could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace DNA Biomed when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back DNA Biomed - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling DNA Biomed Solns to buy it.
The correlation of DNA Biomed is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as DNA Biomed moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if DNA Biomed Solns moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for DNA Biomed can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DNA Biomed Solns. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.
Note that the DNA Biomed Solns information on this page should be used as a complementary analysis to other DNA Biomed's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.

Complementary Tools for DNA Stock analysis

When running DNA Biomed's price analysis, check to measure DNA Biomed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DNA Biomed is operating at the current time. Most of DNA Biomed's value examination focuses on studying past and present price action to predict the probability of DNA Biomed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DNA Biomed's price. Additionally, you may evaluate how the addition of DNA Biomed to your portfolios can decrease your overall portfolio volatility.
Transaction History
View history of all your transactions and understand their impact on performance
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Money Managers
Screen money managers from public funds and ETFs managed around the world
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Please note, there is a significant difference between DNA Biomed's value and its price as these two are different measures arrived at by different means. Investors typically determine if DNA Biomed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DNA Biomed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.